drugset / Trial / NCT04490694
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
It is an exploratory clinical study aimed to evaluate the efficacy and safety of TACE combined with Lenvatinib in the treatment of patients with BCLC stage B and C HCC.Treatment will continue until the death or intolerable toxicity or patients withdrawal of consent,and the target sample size is 54 individuals.
Timeline
- Start
- 2020-03-01
- Primary completion
- 2022-08-01
- Completion
- 2023-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |